Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2019-01-25 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Share Issue/Capital Change Classification · 95% confidence The document is a formal notice regarding the suspension of share registration (shareholder register closure) for Celltrion Pharm. It specifies a record date and the purpose, which is to determine shareholders for a small-scale merger. This type of regulatory disclosure regarding corporate actions and shareholder record dates is standard for general regulatory filings in the Korean market (KRX) and does not fit into specific categories like dividends, share buybacks, or financial reports.
2019-01-25 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. It details the share transactions (specifically a sale of shares) by an executive (Kwon Seok) of Celltrion Pharm. This type of filing is categorized as 'Director's Dealing' (DIRS) as it reports personal share transactions by company insiders.
2018-12-26 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the suspension of share registration (shareholder register closure) for the purpose of determining shareholders for an upcoming Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal regulatory announcement of a corporate action. Given it is a specific regulatory notification that does not fit into the other categories like dividend or share issuance, it is classified as a general regulatory filing.
2018-12-14 Korean
대규모기업집단현황공시[분기별공시(개별회사용)]
Audit Report / Information Classification · 95% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by Celltrion Pharm. This is a mandatory regulatory filing in South Korea required by the Fair Trade Commission to report on group structure, shareholdings, and inter-company transactions. Since it does not fit into specific categories like financial reports (10-K/IR), earnings releases, or shareholder communications, it falls under the 'Regulatory Filings' category. Q1 2024
2018-11-30 Korean
분기보고서 (2018.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Celltrion Pharm, Inc. covering the period from January 1, 2018, to September 30, 2018. It contains detailed financial information, business descriptions, and management disclosures required for a quarterly filing in South Korea. It is not an announcement of a report, but the report itself, and it contains substantive financial data, thus fitting the definition of an Interim/Quarterly Report (IR). 9M 2018
2018-11-14 Korean
특수관계인으로부터받은담보
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing detailing a specific corporate transaction regarding collateral provided by a related party (Celltrion Holdings) to Celltrion Pharm. It includes details on the collateral provider, the nature of the collateral, the creditor (Korea Development Bank), and board approval. As it is a specific regulatory disclosure regarding corporate financing/collateral that does not fit into the other specialized categories like M&A or Share Issues, it falls under the general regulatory filing category.
2018-10-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.